Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma

被引：3

作者：

Mai, Elias K. ^{[1
]}

Hielscher, Thomas ^{[2
]}

Bertsch, Uta ^{[1
]}

Schlenzka, Jana ^{[1
]}

Salwender, Hans J. ^{[3
]}

Munder, Markus ^{[4
]}

Gerecke, Christian ^{[5
]}

Duehrsen, Ulrich ^{[6
]}

Brossart, Peter ^{[7
]}

Neben, Kai ^{[8
]}

Hillengass, Jens ^{[1
]}

Raab, Marc S. ^{[1
]}

Merz, Maximilian ^{[1
]}

Baertsch, Marc-Andrea ^{[1
]}

Jauch, Anna ^{[9
]}

Hose, Dirk ^{[1
]}

Martin, Hans ^{[10
]}

Lindemann, Hans-Walter ^{[11
]}

Blau, Igor W. ^{[12
]}

Scheid, Christof ^{[13
]}

Weisel, Katja C. ^{[14
]}

Goldschmidt, Hartmut ^{[1
,15
]}

机构：

[1] Univ Clin Heidelberg, Dept Internal Med 5, Heidelberg, Germany

[2] German Canc Res Ctr, Div Biostat, Heidelberg, Germany

[3] Asklepios Hosp Hamburg Altona, Dept Hematol & Oncol, Hamburg, Germany

[4] Univ Med Ctr Mainz, Dept Internal Med 3, Mainz, Germany

[5] Helios Hosp Berlin Buch, Dept Hematol & Oncol, Berlin, Germany

[6] Univ Clin Essen, Dept Hematol, Essen, Germany

[7] Univ Hosp Bonn, Bonn, Germany

[8] Klinikum Baden Baden, Dept Hematol & Oncol, Baden Baden, Germany

[9] Heidelberg Univ, Inst Human Genet, Heidelberg, Germany

[10] Goethe Univ Frankfurt, Dept Med Hematol Oncol, Frankfurt, Germany

[11] Katholisches Krankenhaus Hagen, Dept Hematol & Oncol, Hagen, Germany

[12] Charite Univ Med Berlin, Med Clin, Berlin, Germany

[13] Univ Hosp Koln, Dept Internal Med 1, Cologne, Germany

[14] Univ Hosp Tubingen, Dept Hematol Oncol & Immunol, Tubingen, Germany

[15] Natl Ctr Tumorerkrankungen NCT Heidelberg, Heidelberg, Germany

来源：

LEUKEMIA | 2019年 / 33卷 / 01期

关键词：

D O I：

10.1038/s41375-018-0195-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：258 / 261

页数：4

共 50 条

[1] Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma
Elias K. Mai
Thomas Hielscher
Uta Bertsch
Jana Schlenzka
Hans J. Salwender
Markus Munder
Christian Gerecke
Ulrich Dührsen
Peter Brossart
Kai Neben
Jens Hillengass
Marc S. Raab
Maximilian Merz
Marc-Andrea Baertsch
Anna Jauch
Dirk Hose
Hans Martin
Hans-Walter Lindemann
Igor W. Blau
Christof Scheid
Katja C. Weisel
Hartmut Goldschmidt
Leukemia, 2019, 33 : 258 - 261
[2] MAINTENANCE THERAPY WITH BORTEZOMIB/DEXAMETHASONE IN NEWLY DIAGNOSED TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS CARRYING HIGH RISK FEATURES
Mancuso, K.
Tacchetti, P.
Pantani, L.
Rocchi, S.
Rizzello, I.
Caratozzolo, I.
De Cicco, G.
Fusco, A.
Testoni, N.
Terragna, C.
Marzocchi, G.
Martello, M.
Borsi, E.
Dozza, L.
Zamagni, E.
Cavo, M.
HAEMATOLOGICA, 2019, 104 : 50 - 50
[3] Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial
Voorhees, Peter M.
Kaufman, Jonathan L.
Laubach, Jacob
Sborov, Douglas W.
Reeves, Brandi
Rodriguez, Cesar
Chari, Ajai
Silbermann, Rebecca
Costa, Luciano J.
Anderson, Larry D., Jr.
Nathwani, Nitya
Shah, Nina
Efebera, Yvonne A.
Holstein, Sarah A.
Costello, Caitlin
Jakubowiak, Andrzej
Wildes, Tanya M.
Orlowski, Robert Z.
Shain, Kenneth H.
Cowan, Andrew J.
Murphy, Sean
Lutska, Yana
Pei, Huiling
Ukropec, Jon
Vermeulen, Jessica
de Boer, Carla
Hoehn, Daniela
Lin, Thomas S.
Richardson, Paul G.
BLOOD, 2020, 136 (08) : 936 - 945
[4] Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: A multicenter retrospective comparative analysis
Nishimura, Noriko
Suzuki, Kazuhito
Tsukada, Nobuhiro
Nagata, Yasuyuki
Okaduka, Kiyoshi
Mishima, Yuko
Yokoyama, Masahiro
Nishiwaki, Kaichi
Ishida, Tadao
Yano, Shingo
Terui, Yasuhito
Suzuki, Kenshi
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E214 - E215
[5] Integrated analysis of randomized controlled trials evaluating bortezomib + lenalidomide + dexamethasone or bortezomib + thalidomide + dexamethasone induction in transplant-eligible newly diagnosed multiple myeloma
Rosinol, Laura
Hebraud, Benjamin
Oriol, Albert
Colin, Anne-Laurene
Tamayo, Rafael Rios
Hulin, Cyrille
Blanchard, Maria Jesus
Caillot, Denis
Sureda, Anna
Hernandez, Miguel Teodoro
Arnulf, Bertrand
Mateos, Maria-Victoria
Macro, Margaret
San-Miguel, Jesus
Belhadj, Karim
Lahuerta, Juan Jose
Garelik, M. Brigid
Blade, Joan
Moreau, Philippe
FRONTIERS IN ONCOLOGY, 2023, 13
[6] Bortezomib-Dexamethasone vs Bortezomib-Dexamethasone and chemotherapeutic agents in Transplant-Eligible Newly Diagnosed Myeloma
Abril, Laura
Pena, Marta
Ibarra, Gladys
Gassiot, Susanna
Oriol, Albert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E215 - E215
[7] Outcomes of a bortezomib-based induction regimen (sequential or upfront triple association with lenalidomide) in transplant-eligible patients withh newly diagnosed multiple myeloma
Paulos-Mesquita, Isabel
Vieira, Joana
Espada, Eduardo
Martins-Almeida, Pedro
Duarte, Margarida
Lopes-Silva, Catarina
Martins, Helena
Raposo, Joao
Esteves, Graca
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S121 - S121
[8] Should the emphasis be on induction or consolidation therapy in transplant-eligible, newly diagnosed multiple myeloma?
Krishnan, Amrita
LANCET HAEMATOLOGY, 2020, 7 (06): : E445 - E446
[9] Induction Therapy with Bortezomib-Cyclophosphamide-Dexamethasone (BCD) for Newly Diagnosed Transplant Eligible Patients with Multiple Myeloma
Tsukada, Nobuhiro
Ikeda, Masahiro
Shingaki, Sumito
Miyazaki, Kanji
Meshitsuka, Sosuke
Abe, Yu
Yoshiki, Yumiko
Suzuki, Kenshi
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2015, 21 (02) : S205 - S205
[10] Management of induction failures in newly diagnosed transplant-eligible multiple myeloma
Gertz, Morie A.
LEUKEMIA & LYMPHOMA, 2020, 61 (01) : 1 - 3

← 1 2 3 4 5 →